



## REQUIREMENTS FOR ELECTRONIC SUBMISSION OF CASE REPORTS

**DEADLINE: Monday, September 9, 2024, 11:59 PM EDT**

### PRESENTATION FORMATS

This year the Society will again be accepting challenging case reports for Special Interest Group Breakfast Sessions. Please do not submit case reports to the call for abstract submission site for podium consideration.

### CASE REPORT PREPARATION/SUBMISSION INSTRUCTIONS

- Interesting Cases are to be authored, co-authored, or sponsored by a member of SCVS, and limited to 375 words.
- **Please note Case Reports (report on 1-3 patients) must be submitted under the Case Submission Portal. Case reports submitted under the Abstract category will not be considered.**
- The deadline is September 9, 2024, 11:59 PM, EDT.
- Interesting Case Reports will only be eligible for the Special Interest Case Breakfast Sessions.
- All Interesting Case Reports must be structured using the following section headings.

#### DEMOGRAPHICS

#### HISTORY

#### PLAN

#### DISCUSSION

- One table, image or figure may be used within your abstract, and counts for 25 words.
- **No Institutional identifier should be made in the title or within the body of the abstract. Doing so could jeopardize an acceptance to the program.**
- Accepted case reports will appear on the online program and mobile app as submitted.

### CASE CATEGORIES

To facilitate grading/scoring, Challenging Cases are to be submitted in one of the listed categories. There is no quota for any category.

- Abdominal Aortic
- Thoracic Aortic
- Peripheral & Other
- Venous & Dialysis

## DISCLOSURE REQUIREMENTS

One of the founding principles of SCVS is the acknowledgement of interaction between industry and surgeons to facilitate rapid development of technology for vascular surgery and the treatment of vascular disease. In that endeavor, a surgeon may become financially involved with the company that translates his or her idea into reality. SCVS does not object to that relationship, but requires that all those submitting abstracts and presenting papers disclose financial or consulting relationships with companies that may be involved with production or marketing of technology being discussed. The need for disclosure extends to unrestricted laboratory grants. In addition, any off-label use of an FDA-approved product, or any use of a non-FDA approved device must be disclosed.

**When you complete your abstract submission, you will be required to complete relevant disclosure information for all authors.**

## COMMITMENT TO PRESENT

Submission of an abstract constitutes a commitment by the author(s) to present if it is accepted. Failure to present, if not justified, could potentially jeopardize acceptance of future abstract submissions. Only the primary author or a co-author may present the accepted abstract at SCVS 2025.